Invitrogen Nabs BioSource in Bid to Bolster Proteomics; Plans Growth in Europe, Asia | GenomeWeb

Taking another step to build up its proteomics offering, Invitrogen has signed a deal to acquire BioSource International, a provider of proteins, antibodies, and reagents for cytokine and signal transduction assays, for $130 million in cash.

Invitrogen said the acquisition, hatched a few months after BioSource directors roundly rejected a cheaper bid by Invitrogen rival Bio-Rad Laboratories, is designed to bolster its protein and antibody offerings and could help it enter new markets in immunology, oncology, and neurodegenerative disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.